

## SENSITIVE\*: Limited Joint Procurement of medical countermeasures

Dear Members of the Steering Committee for joint procurement of monoclonal antibodies, Dear Members of the Joint Procurement Agreement Steering Committee,

Please find attached a press releases and below a summary from Roche on the results of the phase III testing where data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19:

- Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days
- The 2,400 mg and 1,200 mg doses tested in the phase III study had similar efficacy across all endpoints
- Companion dose-ranging phase II trial showed significant and comparable viral reductions for a range of doses of casirivimab and imdevimab
- The combination of casirivimab and imdevimab is the only monoclonal antibody treatment to retain potency against key emerging variants, based on the recently updated EUA guidance (Emergency Use Authorisation) from the U.S. FDA.

Kind regards,

## **SANTE Joint Procurement Agreement Team**



European Commission | Health and Food Safety | Health Security and Vaccination

LU-2920 Luxembourg | HTC

5.1.2e @ec.europa.eu

<sup>\*</sup> Not for distribution. Do not read or carry openly in public places. Must be stored securely and encrypted in storage and transmission. Destroy copies by shredding or secure deletion. Full handling instructions: <a href="https://europa.eu/!db43PX">https://europa.eu/!db43PX</a>